Retifanlimab versus placebo in combination with platinum-based chemotherapy in patients with first-line non-squamous or squamous metastatic non-small-cell lung cancer (POD1UM-304): a phase 3, multiregional, placebo-controlled, double-blind, randomised study.

Lu S, Vynnychenko O, Kulyaba Y, Kuchava V, Ibrahim A, Moiseenko F, Arslan C, Nguyen DT, Petrovic M, Cicin I, Bibichadze K, Cil T, Shi J, Olmez OF, Gogishvili M, Artac M, Nguyen HG, Cornfeld M, Tian C, Munteanu MC, Sette CVM, Bondarenko I, POD1UM-304 Study Team

Open source

DOI: 10.1016/s2213-2600(25)00209-7
Published: 2025 Dec
Container: The Lancet. Respiratory medicine
Publisher: Not recorded
Open access: no

Credibility signals

limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1016/s2213-2600-25-00209-7,
  title = {Retifanlimab versus placebo in combination with platinum-based chemotherapy in patients with first-line non-squamous or squamous metastatic non-small-cell lung cancer (POD1UM-304): a phase 3, multiregional, placebo-controlled, double-blind, randomised study.},
  author = {Lu S and Vynnychenko O and Kulyaba Y and Kuchava V and Ibrahim A and Moiseenko F and Arslan C and Nguyen DT and Petrovic M and Cicin I and Bibichadze K and Cil T and Shi J and Olmez OF and Gogishvili M and Artac M and Nguyen HG and Cornfeld M and Tian C and Munteanu MC and Sette CVM and Bondarenko I and POD1UM-304 Study Team},
  year = {2025},
  journal = {The Lancet. Respiratory medicine},
  doi = {10.1016/s2213-2600(25)00209-7},
  url = {https://doi.org/10.1016/s2213-2600(25)00209-7}
}

RIS

TY  - JOUR
TI  - Retifanlimab versus placebo in combination with platinum-based chemotherapy in patients with first-line non-squamous or squamous metastatic non-small-cell lung cancer (POD1UM-304): a phase 3, multiregional, placebo-controlled, double-blind, randomised study.
AU  - Lu S
AU  - Vynnychenko O
AU  - Kulyaba Y
AU  - Kuchava V
AU  - Ibrahim A
AU  - Moiseenko F
AU  - Arslan C
AU  - Nguyen DT
AU  - Petrovic M
AU  - Cicin I
AU  - Bibichadze K
AU  - Cil T
AU  - Shi J
AU  - Olmez OF
AU  - Gogishvili M
AU  - Artac M
AU  - Nguyen HG
AU  - Cornfeld M
AU  - Tian C
AU  - Munteanu MC
AU  - Sette CVM
AU  - Bondarenko I
AU  - POD1UM-304 Study Team
PY  - 2025
JO  - The Lancet. Respiratory medicine
DO  - 10.1016/s2213-2600(25)00209-7
UR  - https://doi.org/10.1016/s2213-2600(25)00209-7
ER  -

APA

S, L., O, V., Y, K., V, K., A, I., F, M., C, A., DT, N., M, P., I, C., K, B., T, C., J, S., OF, O., M, G., M, A., HG, N., M, C., C, T., MC, M., CVM, S., I, B., & Team, P. S. (2025). Retifanlimab versus placebo in combination with platinum-based chemotherapy in patients with first-line non-squamous or squamous metastatic non-small-cell lung cancer (POD1UM-304): a phase 3, multiregional, placebo-controlled, double-blind, randomised study.. The Lancet. Respiratory medicine. https://doi.org/10.1016/s2213-2600(25)00209-7

Source records

pubmed · retrieved 2026-09-27T08:38:23.612Z
europe-pmc · retrieved 2026-09-27T08:38:23.624Z